Arrowhead Pharmaceuticals (ARWR) Stock Forecast & Price Target

Arrowhead Pharma is viewed favorably because its RNAi platform is now showing clinical de-risking in both CNS and cardiometabolic programs, with ARO-MAPT delivering up to 73% mean CSF tau reduction at Day 105, no serious TEAEs, and evidence that quarterly subcutaneous dosing could be feasible. Its broader value case is reinforced by plozasiran, which in SHASTA-3/-4 produced 79% and 81% median triglyceride reductions at Month 12, lowered adjudicated acute pancreatitis events by 78% in pooled analysis, and appears positioned for a broader sHTG label supported by a PRV. Financially, the company’s early-commercial pipeline is modeled to generate future revenue through 2036, with an estimated $17.3 billion firm value, while the CNS franchise and at least four additional CNS clinical entrants by end-2027 add meaningful platform optionality.

Arrowhead Pharma is burdened by weak clinical differentiation, as diranersen’s response plateaued above 6.4 mg/kg and the lowest dose performed best in phase II, suggesting deeper knockdown may not translate into better efficacy. Safety also remains a concern, with any TEAE occurring in 90% of Part 1a and 83% of Part 1b ARO-MAPT patients versus 53% on placebo, while headache and injection-site reactions were common and hematology and NfL data were not disclosed. Fundamentally, the company faces continuing cash burn and may need dilutive debt or equity financing, while regulatory, patent, and intense competition risks could all limit commercial success or leave its RNAi pipeline non-competitive.